Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,308 | -2,394 | -1,275 | -6,912 | -4,896 |
| Depreciation Amortization | 83 | 83 | 15 | 50 | 44 |
| Accounts receivable | 54 | 345 | 226 | 345 | 55 |
| Accounts payable and accrued liabilities | -195 | -1,155 | -944 | -213 | -916 |
| Other Working Capital | -141 | -810 | -718 | 132 | -861 |
| Other Operating Activity | 535 | 1,084 | 866 | 461 | 1,335 |
| Operating Cash Flow | $-3,972 | $-2,847 | $-1,830 | $-6,137 | $-5,239 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 4,667 | 1,824 | 432 | 2,300 | 6,947 |
| Purchase Of Investment | -3,329 | N/A | N/A | -1,500 | -8,426 |
| Investing Cash Flow | $1,338 | $1,824 | $432 | $800 | $-1,479 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 8,338 | N/A | N/A | 6,185 | 6,185 |
| Financing Cash Flow | $8,338 | $N/A | $N/A | $6,185 | $6,185 |
| Beginning Cash Position | 2,978 | 2,978 | 2,978 | 2,130 | 2,130 |
| End Cash Position | 8,682 | 1,955 | 1,580 | 2,978 | 1,597 |
| Net Cash Flow | $5,704 | $-1,023 | $-1,398 | $848 | $-533 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,972 | -2,847 | -1,830 | -6,137 | -5,239 |
| Free Cash Flow | -3,972 | -2,847 | -1,830 | -6,137 | -5,239 |